Clinical Outcomes Using RYONCIL (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles…

Key points:

NEW YORK, May 25, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that clinical outcomes of its allogeneic mesenchymal stem cell (MSC) medicine RYONCIL (remestemcel-L) in children and adults with steroid-refractory acute graft versus host disease (GVHD) have been published in three peer-reviewed articles and an accompanying editorial in the May issue of Biology of Blood and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy.

Mesoblast Chief Medical Officer Dr Fred Grossman said: Results from these three trials show a consistent pattern of safety and efficacy for RYONCIL (remestemcel-L) in patients with the greatest levels of inflammation and the most severe grades of acute GVHD. These clinical outcomes provide a compelling rationale for use of remestemcel-L in children and adults with other conditions associated with severe inflammation and cytokine release, including acute respiratory distress syndrome (ARDS) and systemic vascular manifestations of COVID-19 infection.

In the accompanying editorial, Dr Jacques Galipeau, Professor and Assistant Dean of Medicine at the Stem Cell & Regenerative Medicine Center at the University of WisconsinMadison and Chair of the International Society of Cell and Gene Therapy (ISCT) MSC Committee, concluded that after more than a decade of clinical study involving three distinct advanced trials, it appears that remestemcel-L might well have finally met the regulatory requirements for marketing approval in the United States for steroid refractory acute GVHD in children, and it is to be determined whether this industrial MSC product will find utility for adults afflicted by acute GVHD or other indications.

The trials highlighted in the three articles all evaluated the same treatment regimen of RYONCIL, with patients receiving twice weekly intravenous infusions of 2 million cells per kg body weight over a four-week period. RYONCIL was well-tolerated in all studies with no identified safety concerns. The three trials were:

1. Study 275: An Expanded Access Program in 241 children across 50 centers in eight countries where RYONCIL was used as salvage therapy for steroid-refractory acute GVHD in patients who failed to respond to steroid therapy as well as multiple other agents.

2. Study GVHD001/002: A Phase 3 single-arm trial in 55 children across 20 centers in the United States where RYONCIL was used as the first line of treatment for children who failed to respond to steroids for acute GVHD.

3. Study 280: A Phase 3 randomized placebo-controlled trial in 260 patients, including 28 children, across 72 centers in seven countries where RYONCIL or placebo were added to second line therapy in patients with steroid-refractory acute GVHD who failed to respond to steroid treatment.

About Acute Graft Versus Host Disease Acute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). Over 30,000 patients worldwide undergo an allogeneic BMT annually, primarily during treatment for blood cancers, and these numbers are increasing.1 In patients with the most severe form of acute GVHD (Grade C/D or III/IV) mortality is as high as 90% despite optimal institutional standard of care.2,3 There are currently no FDA-approved treatments in the United States for children under 12 with steroid-refractory acute GVHD.

About RYONCILTM Mesoblasts lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions. RYONCIL is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in SR-aGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

References 1. Niederwieser D, Baldomero H, Szer J. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant 2016; 51(6):778-85.2. Westin, J., Saliba, RM., Lima, M. (2011) Steroid-refractory acute GVHD: predictors and outcomes. Advances in Hematology 2011;2011:601953.3. Axt L, Naumann A, Toennies J (2019) Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 2019;54(11):1805-1814.

About MesoblastMesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. The Companys proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblasts Biologics License Application to seek approval of its product candidate RYONCIL (remestemcel-L) for pediatric steroid-refractory acute graft versus host disease (acute GVHD) has been accepted for priority review by the United States Food and Drug Administration (FDA), and if approved, product launch in the United States is expected in 2020. Remestemcel-L is also being developed for other inflammatory diseases in children and adults including moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblasts licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. This IP position is expected to provide the Company with substantial commercial advantages as it develops its product candidates for these conditions.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking StatementsThis announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of Mesoblast and its collaborators clinical studies; Mesoblast and its collaborators ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblasts product candidates, if approved; the potential benefits of strategic collaboration agreements and Mesoblasts ability to maintain established strategic collaborations; Mesoblasts ability to establish and maintain intellectual property on its product candidates and Mesoblasts ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblasts actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For further information, please contact:

Read the original:
Clinical Outcomes Using RYONCIL (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles...

Stem Cell Therapy Market 2020: Consumption, Trends, Growth, Types,Industrial Applications, Leading Companies & Forecast till 2026 – Jewish Life…

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Stem Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Stem Cell Therapy Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Stem Cell Therapy market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Stem Cell Therapy MarketIndustry / Sector Trends

Stem Cell Therapy Market size was valued at USD 7.8 billion in 2018 and is expected to witness 10.2% CAGR from 2019 to 2025.

U.S. Stem Cell Therapy Market Size, By Type, 2018 & 2025 (USD Million)

Rising prevalence of chronic diseases will positively impact the stem cell therapy market growth. Cardiovascular diseases, neurological disorders and other chronic conditions have resulted in high mortality over past few years. Conventional therapeutic methods and treatments are currently replaced due to lack of efficiency and efficacy. Recently developed stem cell therapies are capable of replacing defective cells to treat diseases that has reduced morbidity drastically. Therefore, people have now started relying on stem cell therapy that has long term positive effects.

Advancements in stem cell therapy in developed regions such as North America and Europe have boosted the industry growth. Since past few years, there have been several researches carried out for stem cell therapy. Currently developed stem cell therapies have shown positive outcomes in treatment of leukemia. Similarly, due to advancements in regenerative medicine, several other chronic conditions such as muscular dystrophy and cardiovascular diseases also have been cured. Aforementioned factors have surged the industry growth. However, high cost of allogenic stem cell therapy may hamper the industry growth to some extent.

Market Segmentation, Outlook & Regional Insights: Stem Cell Therapy Market

Stem Cell Therapy Market, By Type

Allogenic stem cell therapy segment held around 39% revenue share in 2018 and it is anticipated to grow substantially during analysis timeframe. Allogenic stem cell is available as off the shelf therapy and it is easily scalable that helps in providing treatment without delay. Moreover, the procedure includes culturing donor-derived immunocompetent cells that are highly effective in treatment of several diseases. Stem cells obtained in allogenic therapy are free of contaminating tumor cells. This reduces risk for disease recurrence that will surge its demand thereby, stimulating segment growth.

Autologous stem cell therapy segment is estimated to witness 10.1% growth over the forthcoming years. People usually prefer autologous stem cell therapy as it has minimum risk of immunological rejection. However, on introduction of allogenic stem cell therapy, demand for autologous stem cell therapy has declined as it is difficult to scale up. However, there are concerns regarding risk of cross contamination during large scale manufacturing of autologous stem cell lines that will impede segmental growth to some extent.

Stem Cell Therapy Market, By Application

Neurology segment was valued around USD 1.6 billion in 2018 and it is estimated that it will witness significant growth over the forthcoming years. Stem cells are used to replenish the disrupted neurological cells that helps in quick patient recovery. Pluripotent stem cells provide replacement for cells and tissues to treat Alzheimers, Parkinsons disease, cerebral palsy, amyotrophic lateral sclerosis and other neurodegenerative diseases. Thus, pivotal role of stem cells in treating life threatening neurological condition will escalate segment growth.

Cardiovascular segment will witness 10% growth over the analysis timeframe. Considerable segmental growth can be attributed to development in stem cell therapies that have enhanced recovery pace in patients suffering from cardiovascular diseases. Recently developed allogenic stem cell therapies are efficient and easily available that have reduced the mortality rates in cardiovascular patients. Above mentioned factors will propel cardiovascular segment growth in near future.

Germany Stem Cell Therapy Market Size, By Application, 2018 (USD Million)

Stem Cell Therapy Market, By End-users

Hospitals segment held over 56% revenue share in 2018 and it is anticipated to grow significantly in near future. Rising preference for stem cell therapies offered by hospitals proves beneficial for the business growth. Hospitals have affiliations with research laboratories and academic institutes that carry out research activities for developing stem cell therapies. On introduction and approval of any novel stem therapy, hospitals implement it immediately. Associations with research and academic institutes further helps hospitals to upgrade its stem cell treatment offerings that positively impacts the segmental growth.

Clinics segment is expected to grow at around 10% during the forecast timeframe. Clinics specializing in providing stem cell therapies are well-equipped with advanced medical devices and superior quality reagents required for imparting stem cell therapies. However, as clinics offer specialized stem cell therapies, their treatment cost is much higher as compared to hospitals that may reduce its preference.

Stem Cell Therapy Market, By Region

North America stem cell therapy market held around 41.5% revenue share in 2018 and it is estimated to grow substantially in near future. Increasing adoption of novel stem cell therapies will prove beneficial for regional market growth. Moreover, favourable government initiatives have positive impact on the regional market growth. For instance, government of Canada has initiated Strategic Innovation Fund Program that invests in research activities carried out for stem cell therapies enabling development in stem cell therapy. Above mentioned factors are expected to drive the North America market growth.

Asia Pacific stem cell therapy market is anticipated to witness 10.8% growth in near future owing to increasing awareness amongst people pertaining to benefits of advanced stem cell therapies. Additionally, favourable initiatives undertaken by several organizations will promote industry players to come up with innovative solutions. For instance, according to Pharma Focus Asia, members of Asia-Pacific Economic Cooperation collaborated with Life Sciences Innovation Forum to involve professionals having expertise in stem cell therapies from academia and research centers to promote developments in stem cell research. Thus, growing initiatives by organizations ensuring availability of new stem cell therapies will foster regional market growth.

Latin America Stem Cell Therapy Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Stem Cell Therapy Market

Key industry players in stem cell therapy market include Astellas Pharma Inc, Cellectis, Celyad, Novadip Biosciences, Gamida Cell, Capricor Therapeutics, Cellular Dynamics, CESCA Therapeutics, DiscGenics, OxStem, Mesoblast Ltd, ReNeuron Group and Takeda Pharmaceuticals. Chief industry players implement several initiatives such as mergers and acquisitions to sustain market competition. Also, receiving approvals for stem cell therapy products from regulatory authorities fosters companys growth. For instance, in March 2018, European Commission approved Takedas Alofisel that is off-the-shelf stem cell therapy. Product approval will help company to gain competitive advantage and capture market share.

Stem Cell Therapy Industry Viewpoint

Stem cells industry can be traced back to 1950s. In 1959 first animals were made by in-vitro fertilization by preserving the stem cells. Till 2000, research was being carried out on stem cells to study its therapeutic effect. In 2000, fund allocations were made to research on cells derived from aborted human foetuses. In the same year, scientists derived human embryonic stem cells from the inner cell mass of blastocytes. Later, in 2010, clinical trials for human embryonic stem cell-based therapy were initiated. As technology progressed, stem cell therapy for treating cancer were developed. However, due to ethical issues, the use of stem cells for curing diseases witnessed slow growth for few years. But as the regulatory scenario changed, people started preferring stem cell therapies due to its better efficacy. Stem cell therapy is in developing stage and has numerous growth opportunities in developing economies with high prevalence of chronic diseases.

Key Insights Covered: Exhaustive Stem Cell Therapy Market1. Market size (sales, revenue and growth rate) of Stem Cell Therapy industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Stem Cell Therapy industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Stem Cell Therapy industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Stem Cell Therapy industry.

Research Methodology: Stem Cell Therapy Market

Quick Read Table of Contents of this Report @ Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read the rest here:
Stem Cell Therapy Market 2020: Consumption, Trends, Growth, Types,Industrial Applications, Leading Companies & Forecast till 2026 - Jewish Life...

Adipose Derived Stem Cell Therapy Market (Impact of COVID-19) Sales To 2026 Anticipeted By Key Players – Surfacing Magazine

The global Adipose Derived Stem Cell Therapy Market research report thoroughly explains each and every aspect related to the Adipose Derived Stem Cell Therapy Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business. The growth trend forecasted on account of a thorough examination offers in-depth information regarding the global Adipose Derived Stem Cell Therapy Market. A pathway of development is offered by the market to the several connected networks of businesses under it, which include different firms, industries, organizations, vendors, distributors, and local manufacturers too. All the key Adipose Derived Stem Cell Therapy Market players compete with each other by offering better products and services at a reasonable price in order to grab significant share at the regional and global level market.

Get a Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/1249

This report sample includesBrief Introduction to the research report.Table of Contents (Scope covered as a part of the study)Top players in the marketResearch framework (presentation)Research methodology adopted by Coherent Market Insights

The report incorporates an estimated impact of strict standards and regulations set by the government over the market in the upcoming years. The market report also comprises exhaustive research done using several analytical tools such as SWOT analysis to identify the market growth pattern.

Top Manufacturers in GlobalAdipose Derived Stem Cell TherapyMarket Includes:BioRestorative Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, among others.

Regions & Countries Mentioned In The Adipose Derived Stem Cell Therapy Market Report:

Key Highlights of the Table of Contents:

Adipose Derived Stem Cell Therapy Market Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global market, years considered, and study objectives. Furthermore, it tuches the segmentation study provided in the report on the basis of the type of product and applications.

Adipose Derived Stem Cell Therapy Market Executive Summary: This section emphasizes on the key studies, market growth rate,Competitive landscape, market drivers, trends, and issues.

Adipose Derived Stem Cell Therapy Market Production by Region: The report provides information related to import and export, production, revenue, and key players of all regional markets studied are covered in this section.

Adipose Derived Stem Cell Therapy Market Profile of Manufacturers: Analysis of each market player profiled is detailed in this section. This also provides SWOT analysis, products, production, value, capacity, and other vital factors of the individual player.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/1249

Table of Contents

Report Overview:It includes the Adipose Derived Stem Cell Therapy market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Adipose Derived Stem Cell Therapy market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Adipose Derived Stem Cell Therapy market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Adipose Derived Stem Cell Therapy market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Get Download PDF Brochure https://www.coherentmarketinsights.com/insight/request-pdf/1249

Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

About CMI:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Coherent Market Insights 1001 4th Ave,#3200 Seattle, WA 98154, U.SPhone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

Read the original here:
Adipose Derived Stem Cell Therapy Market (Impact of COVID-19) Sales To 2026 Anticipeted By Key Players - Surfacing Magazine

Silver Nanoparticle-Induced Apoptosis in ARPE-19 Cells Is Inhibited by | IJN – Dove Medical Press

Juan-Hua Quan,1,* Fei Fei Gao,2,* Hassan Ahmed Hassan Ahmed Ismail,3,* Jae-Min Yuk,2 Guang-Ho Cha,2 Jia-Qi Chu,4 Young-Ha Lee2

1Department of Gastroenterology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang 524-001, Peoples Republic of China; 2Department of Infection Biology and Department of Medical Science, Chungnam National University College of Medicine, Daejeon 301-131, Korea; 3Communicable and Non-Communicable Diseases Control Directorate, Federal Ministry of Health, Khartoum, Sudan; 4Stem Cell Research and Cellular Therapy Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province 524-001, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Young-Ha LeeDepartment of Infection Biology and Department of Medical Science, Chungnam National University College of Medicine 6 Munhwa-Dong, Jung-Gu, Daejeon 35015, KoreaTel +82-42-580-8273Fax +82-42-583-8216Email yhalee@cnu.ac.kr

Purpose: External and internal stimuli easily affect the retina. Studies have shown that cells infected with Toxoplasma gondii are resistant to multiple inducers of apoptosis. Nanoparticles (NPs) have been widely used in biomedical fields; however, little is known about cytotoxicity caused by NPs in the retina and the modulators that inhibit nanotoxicity.Materials and Methods: ARPE-19 cells from human retinal pigment epithelium were treated with silver nanoparticles (AgNPs) alone or in combination with T. gondii. Then, the cellular toxicity, apoptosis, cell cycle analysis, autophagy, ROS generation, NOX4 expression, and MAPK/mTOR signaling pathways were investigated. To confirm the AgNP-induced cytotoxicity in ARPE-19 cells and its modulatory effects caused by T. gondii infection, the major experiments carried out in ARPE-19 cells were performed again using human foreskin fibroblast (HFF) cells and bone marrow-derived macrophages (BMDMs) from NOX4/ mice.Results: AgNPs dose-dependently induced cytotoxicity and cell death in ARPE-19 cells. Apoptosis, sub-G1 phase cell accumulation, autophagy, JNK phosphorylation, and mitochondrial apoptotic features, such as caspase-3 and PARP cleavages, mitochondrial membrane potential depolarization, and cytochrome c release into the cytosol were observed in AgNP-treated cells. AgNP treatment also increased the Bax, Bik, and Bim protein levels as well as NOX4-dependent ROS generation. However, T. gondii-infected ARPE-19 cells inhibited AgNP-induced apoptosis, JNK phosphorylation, sub-G1 phase cell accumulation, autophagy, NOX4-mediated ROS production, and mitochondrial apoptosis. Furthermore, mitochondrial apoptosis was found in AgNP-treated HFF cells and BMDMs, and AgNP-induced mitochondrial apoptosis inhibition via NOX4-dependent ROS suppression in T. gondii pre-infected HFF cells and BMDMs was also confirmed.Conclusion: AgNPs induced mitochondrial apoptosis in human RPE cells combined with cell cycle dysregulation and autophagy; however, these effects were significantly inhibited by T. gondii pre-infection by suppression of NOX4-mediated ROS production, suggesting that T. gondii is a strong inhibitory modulator of nanotoxicity in in vitro models.

Keywords: silver nanoparticles, Toxoplasma gondii, mitochondrial apoptosis, human retinal pigment epithelium, reactive oxygen species, NADPH oxidase 4

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Go here to see the original:
Silver Nanoparticle-Induced Apoptosis in ARPE-19 Cells Is Inhibited by | IJN - Dove Medical Press

Life celebrates 20th anniversary during English Tourism Week – North East Times

May 26, 2020 @ 10:30 by Chloe Holmes

The International Centre for Life in Newcastle upon Tyne, UK, celebrates its 20th anniversary on May 27 with a week of virtual events and activities.

The landmark anniversary for Life home to the popular visitor attraction Life Science Centre, biomedical research facilities and two NHS clinics falls during VisitEnglands English Tourism Week, which this year will focus on supporting the recovery of tourism and raise awareness of the importance, quality and value of the sector to the UK economy.

Lifes Chief Executive, Linda Conlon, said: We had big plans in place to celebrate Life being 20 in 2020, but weve quickly adapted our operations and celebrations to a digital format. Like many others, we will continue to celebrate our birthday under lockdown it just takes a bit more ingenuity and creativity to do so, and theyre skills that lie at the heart of science.

Over the past 20 years, Life has been home to the research team that created the worlds first cloned human embryo; the first fertility clinic in the world licensed to treat patients using mitochondrial replacement therapy, which was also researched and developed onsite; and a pioneering stem cell treatment that has restored the sight of many people. Now, researchers are working onsite to help tackle the COVID-19 pandemic.

Life Science Centre welcomes about 300,000 visitors a year inspiring the next generation of scientists and health heroes, and helping people of all ages to explore science and to discover its relevance to their own lives.

Linda said: The mission of Life Science Centre has never been more crucial than it is today, in the midst of a global pandemic and climate crisis. Science centres can play a valuable role in communicating cutting-edge science to the public.

Lifes virtual celebrations start today [Tuesday 26 May], with a birthday-themed making activity for families to take part in for #LifeGoesONline on Facebook, Twitter or Instagram. For adults, later this evening, Life will host a science-themed virtual pub quiz.

Read more here:
Life celebrates 20th anniversary during English Tourism Week - North East Times

Stem Cell Therapy Market To Boom In Near Future By 2027 Scrutinized In New Research – News Distinct

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including medical devices, pharmaceuticals, healthcare, biotechnology, and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Stem Cell Therapy Market globally. This report on Stem Cell Therapy Market provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcases market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

The stem cell therapy marketwas valued at US$ 1,534.55 million in 2019 and is expected to grow at a CAGR of 16.7% from 2020to 2027 to reach US$ 5,129.66 million by 2027.

Get sample PDF copy at: https://www.theinsightpartners.com/sample/TIPHE100000991/

What is Stem Cell Therapy Market?

Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under controlled environment in the body or a clinical laboratory, these cells divide to form more cells called daughter cells. Due to the advent of modern health science, these cells play a major role in understanding the occurrence of diseases, generation of advanced regenerative medicines, and drug discovery. There are certain sources such as embryo, bone marrow, body fats, and umbilical cord blood amongst others, where stem cells are generated. The global stem cell therapy market is driven by factors such asincreasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines. However, high cost related with stem cell therapy is likely to obstruct the growth of the stem cell therapymarket during the forecast period. The growing research and development activities in Asia Pacific region is expected to offer huge growth opportunity for stem cell therapy market.

Researchers are further investigating stem cell therapy in autoimmune disorder. Other adult stem cells based treatments are under clinical trials. Hematopoietic stem cells are currently used for treating more than 80 medical diseases, which include diseases of the immune system, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers like leukemia, lymphoma, etc.Emerging Players in the Stem Cell Therapy Market Research include:

A factor which can be a restraint for Stem Cell Therapy Market can be some companies do not collaborate with service providers or they dont take advantage of digitization as they dont have awareness for the same. Nevertheless, digitization in services is opting by an online company to know more exactly about consumer behavior plus it makes business policies flexible to adopt changes as per the market condition on which success and growth of an organization depend which will give more growth opportunities in coming years.

This report will help you determine and analyze your portfolio of key market players with information such as company profile, components and services offered, financial information from the past three years, and key developments it helps you to develop a strategy to gain a competitive edge in the past 5 years. The market payers from Stem Cell Therapy Market are anticipated to lucrative growth opportunities in the future with the rising demand for Stem Cell Therapy Market in the global market.

Key questions answered by this report:

Global Stem Cell Therapy Market By Type

Global Stem Cell Therapy Market By Treatment

Global Stem Cell Therapy Market ByApplication

Global Stem Cell Therapy Market By End User

Global Stem Cell TherapyMarket By Geography

Stem Cell Therapy Market Table of Contents:

Purchase Full Copy of this Report @ https://www.theinsightpartners.com/buy/TIPHE100000991/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: [emailprotected]

Original post:
Stem Cell Therapy Market To Boom In Near Future By 2027 Scrutinized In New Research - News Distinct

Retinitis Pigmentosa Treatment Market : Growth factor with key drivers, industry research, regional forecast – Jewish Life News

QY Research as of late produced a research report titled, Retinitis Pigmentosa Treatment . The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information. The global Retinitis Pigmentosa Treatment market is relied upon to develop generously and flourish as far as volume and incentive during the gauge time frame. The report will give a knowledge about the development openings and controls that will build the market. Pursuers can increase important perception about the eventual fate of the market.

Key companies that are operating in the global Retinitis Pigmentosa Treatment market are: Astellas Pharma Inc., Caladrius Biosciences, Inc., Dompe Farmaceutici S.p.A., Genable Technologies Limited, Genethon, GenSight Biologics S.A., Grupo Ferrer Internacional, S.A., ID Pharma Co., Ltd., InFlectis BioScience, International Stem Cell Corporation, Ionis Pharmaceuticals, Inc., Ms Science Corporation, Mimetogen Pharmaceuticals Inc., Nanovector s.r.l., Orphagen Pharmaceuticals, Inc., etc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1786433/covid-19-impact-on-retinitis-pigmentosa-treatment-market

Segmental Analysis

The report incorporates significant sections, for example, type and end user and a variety of segments that decide the prospects of the market. Each type provide data with respect to the business esteem during the conjecture time frame. The application area likewise gives information by volume and consumption during the estimate time frame. The comprehension of this segment direct the readers in perceiving the significance of variables that shape the market development.

Global Retinitis Pigmentosa Treatment Market Segment By Type:

, BNP-RP, Cenegermin, CPK-850, Cutamesine, FAB-111, Others

Global Retinitis Pigmentosa Treatment Market Segment By Application:

, Hospital, Clinic, Homecare

Competitive Landscape

The report incorporates various key players and producers working in the local and worldwide market. This segment shows the procedures received by players in the market to remain ahead in the challenge. New patterns and its reception by players assist readers with understanding the elements of the business and how it very well may be utilized to their own benefit. The readers can likewise recognize the strides of players to comprehend the global market better.

Key companies operating in the global Retinitis Pigmentosa Treatment market include Astellas Pharma Inc., Caladrius Biosciences, Inc., Dompe Farmaceutici S.p.A., Genable Technologies Limited, Genethon, GenSight Biologics S.A., Grupo Ferrer Internacional, S.A., ID Pharma Co., Ltd., InFlectis BioScience, International Stem Cell Corporation, Ionis Pharmaceuticals, Inc., Ms Science Corporation, Mimetogen Pharmaceuticals Inc., Nanovector s.r.l., Orphagen Pharmaceuticals, Inc., etc.

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1786433/covid-19-impact-on-retinitis-pigmentosa-treatment-market

TOC

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Retinitis Pigmentosa Treatment Industry1.7 COVID-19 Impact: Retinitis Pigmentosa Treatment Market Trends 2 Global Retinitis Pigmentosa Treatment Quarterly Market Size Analysis2.1 Retinitis Pigmentosa Treatment Business Impact Assessment COVID-192.1.1 Global Retinitis Pigmentosa Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Retinitis Pigmentosa Treatment Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 By Players, Global Retinitis Pigmentosa Treatment Quarterly Market Size, 2019 VS 20203.2 By Players, Retinitis Pigmentosa Treatment Headquarters and Area Served3.3 Date of Key Players Enter into Retinitis Pigmentosa Treatment Market3.4 Key Players Retinitis Pigmentosa Treatment Product Offered3.5 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Retinitis Pigmentosa Treatment Segments, By Type4.1 Introduction1.4.1 BNP-RP1.4.2 Cenegermin1.4.3 CPK-8501.4.4 Cutamesine1.4.5 FAB-1111.4.6 Others4.2 By Type, Global Retinitis Pigmentosa Treatment Market Size, 2019-2021 5 Impact of Covid-19 on Retinitis Pigmentosa Treatment Segments, By Application5.1 Overview5.5.1 Hospital5.5.2 Clinic5.5.3 Homecare5.2 By Application, Global Retinitis Pigmentosa Treatment Market Size, 2019-20215.2.1 By Application, Global Retinitis Pigmentosa Treatment Market Size by Application, 2019-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 Astellas Pharma Inc.7.1.1 Astellas Pharma Inc. Business Overview7.1.2 Astellas Pharma Inc. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.1.3 Astellas Pharma Inc. Retinitis Pigmentosa Treatment Product Introduction7.1.4 Astellas Pharma Inc. Response to COVID-19 and Related Developments7.2 Caladrius Biosciences, Inc.7.2.1 Caladrius Biosciences, Inc. Business Overview7.2.2 Caladrius Biosciences, Inc. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.2.3 Caladrius Biosciences, Inc. Retinitis Pigmentosa Treatment Product Introduction7.2.4 Caladrius Biosciences, Inc. Response to COVID-19 and Related Developments7.3 Dompe Farmaceutici S.p.A.7.3.1 Dompe Farmaceutici S.p.A. Business Overview7.3.2 Dompe Farmaceutici S.p.A. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.3.3 Dompe Farmaceutici S.p.A. Retinitis Pigmentosa Treatment Product Introduction7.3.4 Dompe Farmaceutici S.p.A. Response to COVID-19 and Related Developments7.4 Genable Technologies Limited7.4.1 Genable Technologies Limited Business Overview7.4.2 Genable Technologies Limited Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.4.3 Genable Technologies Limited Retinitis Pigmentosa Treatment Product Introduction7.4.4 Genable Technologies Limited Response to COVID-19 and Related Developments7.5 Genethon7.5.1 Genethon Business Overview7.5.2 Genethon Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.5.3 Genethon Retinitis Pigmentosa Treatment Product Introduction7.5.4 Genethon Response to COVID-19 and Related Developments7.6 GenSight Biologics S.A.7.6.1 GenSight Biologics S.A. Business Overview7.6.2 GenSight Biologics S.A. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.6.3 GenSight Biologics S.A. Retinitis Pigmentosa Treatment Product Introduction7.6.4 GenSight Biologics S.A. Response to COVID-19 and Related Developments7.7 Grupo Ferrer Internacional, S.A.7.7.1 Grupo Ferrer Internacional, S.A. Business Overview7.7.2 Grupo Ferrer Internacional, S.A. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.7.3 Grupo Ferrer Internacional, S.A. Retinitis Pigmentosa Treatment Product Introduction7.7.4 Grupo Ferrer Internacional, S.A. Response to COVID-19 and Related Developments7.8 ID Pharma Co., Ltd.7.8.1 ID Pharma Co., Ltd. Business Overview7.8.2 ID Pharma Co., Ltd. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.8.3 ID Pharma Co., Ltd. Retinitis Pigmentosa Treatment Product Introduction7.8.4 ID Pharma Co., Ltd. Response to COVID-19 and Related Developments7.9 InFlectis BioScience7.9.1 InFlectis BioScience Business Overview7.9.2 InFlectis BioScience Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.9.3 InFlectis BioScience Retinitis Pigmentosa Treatment Product Introduction7.9.4 InFlectis BioScience Response to COVID-19 and Related Developments7.10 International Stem Cell Corporation7.10.1 International Stem Cell Corporation Business Overview7.10.2 International Stem Cell Corporation Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.10.3 International Stem Cell Corporation Retinitis Pigmentosa Treatment Product Introduction7.10.4 International Stem Cell Corporation Response to COVID-19 and Related Developments7.11 Ionis Pharmaceuticals, Inc.7.11.1 Ionis Pharmaceuticals, Inc. Business Overview7.11.2 Ionis Pharmaceuticals, Inc. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.11.3 Ionis Pharmaceuticals, Inc. Retinitis Pigmentosa Treatment Product Introduction7.11.4 Ionis Pharmaceuticals, Inc. Response to COVID-19 and Related Developments7.12 Ms Science Corporation7.12.1 Ms Science Corporation Business Overview7.12.2 Ms Science Corporation Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.12.3 Ms Science Corporation Retinitis Pigmentosa Treatment Product Introduction7.12.4 Ms Science Corporation Response to COVID-19 and Related Developments7.13 Mimetogen Pharmaceuticals Inc.7.13.1 Mimetogen Pharmaceuticals Inc. Business Overview7.13.2 Mimetogen Pharmaceuticals Inc. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.13.3 Mimetogen Pharmaceuticals Inc. Retinitis Pigmentosa Treatment Product Introduction7.13.4 Mimetogen Pharmaceuticals Inc. Response to COVID-19 and Related Developments7.14 Nanovector s.r.l.7.14.1 Nanovector s.r.l. Business Overview7.14.2 Nanovector s.r.l. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.14.3 Nanovector s.r.l. Retinitis Pigmentosa Treatment Product Introduction7.14.4 Nanovector s.r.l. Response to COVID-19 and Related Developments7.15 Orphagen Pharmaceuticals, Inc.7.15.1 Orphagen Pharmaceuticals, Inc. Business Overview7.15.2 Orphagen Pharmaceuticals, Inc. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.15.3 Orphagen Pharmaceuticals, Inc. Retinitis Pigmentosa Treatment Product Introduction7.15.4 Orphagen Pharmaceuticals, Inc. Response to COVID-19 and Related Developments 8 Key Findings 9 Appendix9.1 About US9.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View original post here:
Retinitis Pigmentosa Treatment Market : Growth factor with key drivers, industry research, regional forecast - Jewish Life News

COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026 – Jewish Life News

In this report, the COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026. COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market has been broken down by major regions, with complete market estimates on the basis of products/applications on a regional basis.

Browse full research report at https://www.crystalmarketreport.com/covid-19-impact-on-global-stem-cell-and-platelet-rich-plasma-prp-alopecia-therapies-market-size-status-and-forecast-2020-2026

Platelet-rich plasma (PRP) has emerged as a new treatment modality in regenerative plastic surgery, and preliminary evidence suggests that it might have a beneficial role in hair regrowth.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyses the impact of Coronavirus COVID-19 on the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry.

Based on our recent survey, we have several different scenarios about the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market in terms of revenue.

Players, stakeholders, and other participants in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.

Regional and Country-level Analysis

The report offers an exhaustive geographical analysis of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market.

The following players are covered in this report:

Orange County Hair Restoration Center

Hair Sciences Center of Colorado

Anderson Center for Hair

Evolution Hair Loss Institute

Savola Aesthetic Dermatology Center

Virginia Surgical Center

Hair Transplant Institute of Miami

Colorado Surgical Center & Hair Institute

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Breakdown Data by Type

Platelet Rich Plasma Injections

Stem Cell Therapy

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Breakdown Data by Application

Dermatology Clinics

Hospitals

Browse full research report at https://www.crystalmarketreport.com/covid-19-impact-on-global-stem-cell-and-platelet-rich-plasma-prp-alopecia-therapies-market-size-status-and-forecast-2020-2026

Reasons to Buy This Research Report

About Crystal Market Reports

Crystal Market Reports is a distributor of market research spanning 160 industries. Our extensive database consists of over 400,000 quality publications sourced from 400 plus publishers, this puts our research specialists in the unique position of been able to offer truly unbiased advice on what research provides the most valuable insights.

Contact Info.:-

Address: 911 Central Avenue #268Albany New York 12206Email: [emailprotected]Phone: 1-518-730-1569Web: https://www.crystalmarketreport.com

Continued here:
COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026 - Jewish Life News